These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1958442)

  • 1. The bioavailability of sustained release nicotinic acid formulations.
    Neuvonen PJ; Roivas L; Laine K; Sundholm O
    Br J Clin Pharmacol; 1991 Oct; 32(4):473-6. PubMed ID: 1958442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of excretion of nicotinuric acid after ingestion of two controlled release nicotinic acid preparations in man.
    Figge HL; Figge J; Souney PF; Sacks FM; Shargel L; Janosik JE; Kaul AF
    J Clin Pharmacol; 1988 Dec; 28(12):1136-40. PubMed ID: 3243933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
    Menon R; Tolbert D; Cefali E
    Biopharm Drug Dispos; 2007 Sep; 28(6):297-306. PubMed ID: 17571283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation.
    Menon RM; Adams MH; González MA; Tolbert DS; Leu JH; Cefali EA
    Int J Clin Pharmacol Ther; 2007 Aug; 45(8):448-54. PubMed ID: 17725178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action?
    Stern RH; Freeman D; Spence JD
    Metabolism; 1992 Aug; 41(8):879-81. PubMed ID: 1640866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers.
    Kesisoglou F; Rossenu S; Farrell C; Van Den Heuvel M; Prohn M; Fitzpatrick S; De Kam PJ; Vargo R
    J Pharm Sci; 2014 Nov; 103(11):3713-3723. PubMed ID: 25256703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity associated with sustained-release niacin.
    Dalton TA; Berry RS
    Am J Med; 1992 Jul; 93(1):102-4. PubMed ID: 1626557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the pharmacokinetics of two different formulations of extended-release niacin.
    Lauring B; Rosko K; Luo WL; Wenning L; Kissling J; Roupe K; Paolini JF; Wagner J; Lai E
    Curr Med Res Opin; 2009 Jan; 25(1):15-22. PubMed ID: 19210135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia.
    McCormack PL; Keating GM
    Drugs; 2005; 65(18):2719-40. PubMed ID: 16392885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic toxicity of unmodified and time-release preparations of niacin.
    Rader JI; Calvert RJ; Hathcock JN
    Am J Med; 1992 Jan; 92(1):77-81. PubMed ID: 1731514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin.
    Henkin Y; Johnson KC; Segrest JP
    JAMA; 1990 Jul; 264(2):241-3. PubMed ID: 2355446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of side effects with regular and sustained-release nicotinic acid.
    Gibbons LW; Gonzalez V; Gordon N; Grundy S
    Am J Med; 1995 Oct; 99(4):378-85. PubMed ID: 7573093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites.
    Menon RM; González MA; Adams MH; Tolbert DS; Leu JH; Cefali EA
    J Clin Pharmacol; 2007 Jun; 47(6):681-8. PubMed ID: 17463214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioavailability of four modified-release ursodeoxycholic acid preparations for once-a-day administration.
    Simoni P; Sabatini L; Baraldini M; Mirasoli M; Roda A; Roda E
    Int J Clin Pharmacol Res; 2002; 22(2):37-45. PubMed ID: 12503774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations.
    Woodcock BG; Habedank WD; Loh W; Herrmann W; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):660-3. PubMed ID: 3436686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of niacin, simvastatin and their metabolites in healthy Chinese subjects after single and multiple doses of a fixed dose combination tablet of niacin extended release/simvastatin.
    Liu M; Wang XL; Zhang D; Yang M; Han J; Zhang YN; Wang ZL; Liu HC
    Drug Res (Stuttg); 2014 Jun; 64(6):296-300. PubMed ID: 24154936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of the bioavailability and the pharmacodynamic effect of five allopurinol preparations (author's transl)].
    Jaeger H; Russmann D; Rasper J; Blome J
    Arzneimittelforschung; 1982; 32(4):438-43. PubMed ID: 6896646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans.
    Fangmann D; Theismann EM; Türk K; Schulte DM; Relling I; Hartmann K; Keppler JK; Knipp JR; Rehman A; Heinsen FA; Franke A; Lenk L; Freitag-Wolf S; Appel E; Gorb S; Brenner C; Seegert D; Waetzig GH; Rosenstiel P; Schreiber S; Schwarz K; Laudes M
    Diabetes Care; 2018 Mar; 41(3):398-405. PubMed ID: 29212824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.
    Mullin GE; Greenson JK; Mitchell MC
    Ann Intern Med; 1989 Aug; 111(3):253-5. PubMed ID: 2665592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.